What Ybrain does

Ybrain (주식회사 와이브레인) is a South Korean neurotechnology company founded in 2013 that develops and commercializes non-invasive brain stimulation medical devices for diagnosing and treating neuropsychiatric conditions, primarily depression and migraine. Its core technology stack combines transcranial electrical stimulation (tES/tDCS), transcranial nerve stimulation (tNS), and electroencephalography (EEG) into a hospital-to-home treatment platform branded as MINDD. The product portfolio includes MINDD STIM+ (FDA PMA-approved tDCS device for depression, 62.8% remission rate in 6-week home treatment), MINDD SCAN (wireless EEG diagnostic system), DOOPANG/두팡 (TENS device for migraine, 61.7% pain relief within 2 hours), KLAR (mental wellness self-care app), and POLA (consumer device line). Ybrain holds 45+ domestic and international patents and has secured the only three MFDS-approved confirmatory clinical trials for electronic drugs in Korea, plus 21 exploratory trials.

The company operates a multi-channel go-to-market model combining B2B direct sales to hospitals and psychiatric clinics with B2C e-commerce (shop.ybrain.com), a B2B medical institution portal (bizshop.ybrain.com), pharmacy distribution, and retail partnerships including GS Shop live shopping. Revenue is generated primarily through hardware device sales and recurring consumables (hydrogel patches), supplemented by subscription-based clinic services. MINDD STIM+ requires prescription and is distributed through medical channels, while Doopang is available direct-to-consumer without prescription. The company has achieved substantial Korean market penetration with solutions deployed across 767 psychiatric clinics (approximately 35% of Korea's psychiatry departments), 250+ partner hospitals, and cumulative prescription/measurement records exceeding 1.4 million cases. Ybrain is pursuing FDA approval for the U.S. market and has raised 33.6 billion KRW (~$25M) in total funding, including an 11 billion KRW pre-IPO round in February 2022 from Ceragem, Intervest, and KT&G, with plans for a KOSDAQ listing. The company is headquartered in Seongnam (Pangyo Techno Valley) with manufacturing in Daejeon and operates with 11-50 employees.

Name

Ybrain

Legal name

주식회사 와이브레인

Website

https://ybrain.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Ybrain is a South Korean neurotech company that develops non-invasive brain stimulation medical devices (tDCS, TENS, EEG) for diagnosing and treating depression and migraine, serving psychiatric hospitals, clinics, and consumers across Korea with hospital-to-home treatment platforms.

Ownership category

akta.pro rank

Product category

Neuromodulation medical devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Ambulatory Health Care Services (6219)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industries

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Headache & Migraine Medicine (HLAKAIAE)

Keywords

• Non-invasive brain stimulation
• Depression treatment devices
• Neuromodulation medical devices
• EEG brain measurement systems
• Mental health platforms

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Sales: Sale of electronic drug medical devices (MINDD STIM+, Doopang, MINDD SCAN) to hospitals, clinics, and consumers. Devices sold directly through e-commerce platforms and medical institution portals, with B2B channel through bizshop for medical institutions.
2. Consumables and Accessories: Recurring revenue from consumable patches (hydrogel patches) for Doopang and MINDD STIM+ devices. Patches typically last approximately 10 uses per unit.
3. Clinic/Professional Services: MINDD platform providing total mental health solutions to medical institutions including brain wave scanning, stimulation treatment, and data management.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Ybrain designs, manufactures, and sells non-invasive brain stimulation medical devices (electronic drugs) and an integrated mental healthcare platform for the diagnosis and treatment of neuropsychiatric conditions. Its core commercial products are MINDD STIM+ (a tDCS device for major depressive disorder with 62.8% remission rate), MINDD SCAN (a wireless EEG measurement and diagnostic system), and DOOPANG (a TENS device for migraine relief with 61.7% pain relief rate), supported by the KLAR self-care app and the broader MINDD platform for hospital-home linked treatment and data-based symptom management.

Product overview

Ybrain is a mental healthcare technology company offering an integrated platform of electronic drug (전자약) products based on non-invasive brain stimulation technologies. The core product portfolio consists of MINDD STIM+ (tDCS device for depression treatment), MINDD SCAN (wireless EEG brain measurement system), DOOPANG (TENS device for migraine relief), and KLAR (self-care mental wellness app). These products are unified under the MINDD platform, which provides hospital-home linked brain stimulation therapy with data-based personalized symptom management. Ybrain's solutions cover the full mental healthcare spectrum from diagnosis (EEG, HRV testing) to treatment (tDCS, TENS) and ongoing self-care management.

Differentiator

Problem solved

Functional benefit

Brands

• MINDD: Platform brand encompassing MINDD STIM+ (depression treatment device) and MINDD SCAN (brain wave measurement system)
• DOOPANG (두팡)
• KLAR
• POLA
• 전자약국
• 전자약국 비즈샵

Products and services

• MINDD STIM+ A transcranial Direct Current Stimulation (tDCS) medical device that delivers micro-current-based neural regulation to treat depression and other psychiatric conditions. FDA-approved under PMA pathway and MFDS-approved, clinically validated with 62.8% remission rate in 6-week home-based treatment trials. Prescribed by psychiatrists and used in hospitals and at home.
• MINDD SCAN A wireless EEG (electroencephalography) measurement system that enables rapid brain signal recording and real-time brain state analysis for diagnostic support. Supports one-stop non-invasive brain wave testing, HRV examination, and automated analysis reports for hospitals and clinics.
• DOOPANG (두팡) A TENS (Transcutaneous Electrical Nerve Stimulation) device for migraine relief and prevention. MFDS-approved medical device that reduces migraine frequency and alleviates pain, with 61.7% pain relief rate reported within 2 hours of use. Available directly to consumers without prescription through shop.ybrain.com, GS Shop, and pharmacies.
• MINDD Platform An integrated mental healthcare platform combining MINDD STIM+, MINDD SCAN, and related services. Enables hospital-home linked brain stimulation therapy and supports data-based personalized symptom management for medical institutions. Deployed at 767 clinics covering 35% of South Korea's psychiatry departments with 140,000+ prescriptions and measurements.

Quantifiable outcome

• 62.8% remission rate in 6-week home-based depression treatment with MINDD STIM+
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Korea BCCI AssociationcoreStrategic or Co-development Partner · 16 June 2026Ybrain joined as founding member of the Korea Brain-Computer Interface Association, launched in Seoul on June 16. Association brings together industry, medical, and academic participants to advance BCI development under K-Moonshot program. Ybrain, along with Wybrain, Dynamic Solutions, and Serrajem, joined hospitals and universities as founding members. Association plans to develop industrial policies, support joint R&D, standardize activities internationally, and foster professionals.
• DGIST (Daegu Gyeongbuk Institute of Science and Technology)coreStrategic or Co-development Partner · 2 June 2026MOU signed June 2, 2026 for joint development of next-generation Brain-Computer Interface (BCI) technology. Partnership combines DGIST's biomedical engineering research infrastructure and GMP-certified facilities with Ybrain's neurotechnology and medical device commercialization capabilities. Aims to establish full-cycle cooperative framework from R&D to validation and commercialization of BCI technology, supporting the government's K-Moonshot initiative.
• Dynamic SolutionscoreStrategic or Co-development Partner · 10 April 2026Strategic MOU for BCI technology commercialization. Development of precision control technology based on brain neural signals, BCI and AI robotics technology convergence for enabling paraplegic patients to control machines with thoughts, visual/auditory restoration technology, and applications in wearable robots, defense robots, and industrial robotics. Dynamic Solutions is the second-largest shareholder after Serrajem.
• Ministry of Science and ICT (K-Moonshot Project)coreStrategic or Co-development Partner · 11 March 2026Ybrain signed business agreement as the sole industry partner in the brain-computer interface field for the Ministry's K-Moonshot project. The project involves 600 billion KRW in government funding. Ybrain will use its non-invasive brain stimulation technology and clinical data to establish technical standards and build a brain science ecosystem, with plans to develop invasive BCI commercialization to compete with Neuralink.
• SerrajemminorStrategic or Co-development PartnerLargest shareholder in Ybrain. Serrajem joined Ybrain as a strategic partner and is currently the largest shareholder.
• Jeil Pharma (종근당)minorChannel Partner/ Reseller/ DistributorJoint sales partnership for MINDD STIM+ distribution through Jeil Pharma's pharmaceutical sales network, leveraging their CNS business network for hospital sales.
• Korea University ( 고려대학교)minorStrategic or Co-development PartnerCollaboration with Professor Ji Il-joo's team for development of high-density wireless BCI system using 512-channel brain wave signal reading with mesh electrode attachment (partial brain implantation/partial invasive method).

Scale indicators14 records

Recent moves2 records

Expansion highlights6 records

Market position

Strengths5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCPzmpczJT2KlilGc9HJh4xA/featured
• Instagraminstagram.com/ybrain_korea
• Facebookfacebook.com/ybrain.inc
• LinkedInlinkedin.com/company/ybrain

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ybrain